ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2328

Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?

Fadi Kharouf1, Virginia Carrizo Abarza2, Shangyi Gao3, Daniel Pereira4, Richard Cook5, Vinod Chandran6 and Dafna Gladman7, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5University of Waterloo, Waterloo, Canada, 6University of Toronto, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Damage Index, Outcome measures, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and joint manifestations occur simultaneously, and in 7-20% arthritis precedes the skin psoriasis. We aimed to evaluate the differences in demographic characteristics and the impact on disease activity and structural damage in patients who develop PsA before Ps versus those diagnosed with Ps before PsA.

Methods: We included PsA patients from our prospective observational cohort and classified them into two groups based on the onset sequence: those who had PsA before Ps and those who developed Ps before PsA. Patients diagnosed with both psoriasis and PsA within the same year were included in the latter group. We compared baseline demographic and disease-related characteristics between the groups. Multivariate linear regression was used for the 5-year adjusted mean swollen joint count (SJC) and cox proportional hazards analysis for time to radiographic progression was conducted to explore the association between PsA before Ps group with disease activity and damage, respectively compared to Ps before PsA group.

Results: Of the 1702 patients included in the study, 147 (8.6%) developed PsA before Ps. Regarding the baseline characteristics, nail disease and psoriasis area and severity index (PASI) were more prevalent in the Ps before PsA group compared to the other group. The modified Steinbrocker score was significantly higher in patients who developed PsA before Ps, and erosions were more frequent in the same group. Additionally, HLA-B*27 positivity was more common and HLA-C*06 positivity less common in the PsA before Ps group (Table 1).
There was no significant difference between the two groups in the 5-year adjusted mean SJC (estimate -0.40, p= 0.23). However, longer duration of psoriasis, HLA-B*27 positivity and the use of csDMARDs were associated with higher disease activity (Table 2).
PsA before Ps patients showed a hazard ratio (HR) of 1.43 (p=0.023), indicating a significant association with faster progression of radiographic damage. Patients with older age, increased SJC, and a higher baseline modified Steinbrocker score showed a significant association with radiographic progression, as well as the presence of dactylitis. Use of advanced therapy was protective (HR 0.58, p < 0.001) (Table 3).

Conclusion: Only a minority of patients develop PsA before Ps. Compared to those who develop Ps before PsA, patients who develop PsA first exhibit different disease-related characteristics and experience faster progression of radiographic damage.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: F. Kharouf: None; V. Carrizo Abarza: None; S. Gao: None; D. Pereira: None; R. Cook: None; V. Chandran: AbbVie/Abbott, 1, 5, AstraZeneca, 12, Spousal employment, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 1, Janssen, 1, Novartis, 1, UCB, 1; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Kharouf F, Carrizo Abarza V, Gao S, Pereira D, Cook R, Chandran V, Gladman D. Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes? [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/do-patients-that-develop-psa-before-psoriasis-have-different-disease-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-patients-that-develop-psa-before-psoriasis-have-different-disease-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology